Comment

A new analysis released during World Immunisation Week 2026 has sharpened the focus on a persistent weakness in Australia’s health system, highlighting a gap between strong early-stage vaccine research and its translation into real-world outcomes.

Under the agreement, CLEO will build on its existing work using Bio-Techne’s Ella platform, which the company has been using in-house and which has demonstrated the ability to deliver CLEO’s biomarker panel with high sensitivity, precision, and reproducibility.

Algorae said the collaboration establishes a framework for joint prioritisation of products based on regulatory pathways, supply readiness and market access considerations.

Managing director Paul Rennie said the level of investor support underscored confidence in the company’s Phase 3 program and its upcoming interim analysis.

The company said VP-001 has the potential to become the first approved treatment for patients with RP11, a genetic eye disease with no available therapies.

ImmVirX has used one of the world’s largest cancer research stages to sharpen its pitch that oncolytic RNA immunotherapies could materially shift outcomes in some of the most difficult-to-treat tumours.

Amplia Therapeutics has used one of the world’s largest oncology stages to sharpen its case for narmafotinib, presenting mature data from its ACCENT trial that suggest the drug could meaningfully shift outcomes in one of the most difficult-to-treat cancers.

The company has been examining in greater detail how often the treatment may need to be administered, with a focus on identifying an optimal dosing regimen as it prepares the next stage of clinical development and regulatory engagement.

The expansion follows fresh preliminary data from a new cohort of six patients with squamous cell carcinoma, which continued to reinforce a favourable safety profile alongside early signs of efficacy.

The trial, known as R327 G301, is progressing across five sites in Indonesia, with patient dosing ongoing and an interim analysis planned once 155 patients have been completed.

Trajan Group Holdings has announced the appointment of long-time executive Simon Billingham as Interim Chief Financial Officer and Interim Joint Company Secretary following the departure of Alister Hodges.

The Melbourne-based biotechnology company confirmed that a recent Type C meeting with the regulator received positive feedback on both the proposed phase 1 trial design and the broader clinical strategy for DEP HER2, a dendrimer-based radioligand therapy for difficult-to-treat cancers.